antiviral and associated therapy living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study

	COVID-19 severe or critically

	COVID 19 outpatients
antiviral and associated therapy
azithromycin	Hinks ... PRINCIPLE Espitia-Hernandez ACTION
chloroquine and derivatives	ALBERTA HOPE-Covid19
hydroxychloroquine	COVID-PEP Severity ... Q-PROTECT -HCQ alone Agusti BCN PEP-CoV-2-Study 2 ... COMIHY Reis ... NCT04597775 PATCH Cohort 1 ... COPE – Coalition V
fluvoxamine	COVID-OUT ... TOGETHER ACTIV-6 Lenze ...
hydroxychloroquine plus macrolides	NCT04621461
azithromycin plus hydroxychloroquine	Q-PROTECT ... Q-PROTECT -AZI ... Rodrigues
ivermectin	ACTIV-6 ... Podder Chahla Chaccour TOGETHER ... Buonfrate ... IVERCORCOVID19 ... Lopez-Medina Espitia-Hernandez ACTIV 6 ivermectin COVID-OUT ...
ivermectin plus doxycycline	Chowdhury A
lopinavir/ritonavir	Reis ...
molnupiravir	Fischer ... MOVe-OUT
nirmatrelvir / ritonavir (Paxlovid)	EPIC-HR
nitazoxanide	RM08-3008 ...
remdesivir	PINETREE ...
sofosbuvir and daclatasvir	Roozbeh
umifenovir (arbidol)	Ramachandran
zinc	Thomas ...

6625	Nasir, 2020	2	31	0	excluded	not a RCT	risk of bias not avaialble
7314	Samaha, 2021	2	1	3	excluded		high risk of bias